7Chen HS, Wu TE, Jap TS,et al. Beneficial effects of insulin on glycemic control and beta-eell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care, 2008,31 (10): 1 927-1 932.
8中华医学会糖尿病学分会.中国2型糖尿病防治指南(2007年版).
9Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/ AACE Diabetes Road Map Task Force. Endocr Pract, 2007,13 (3):260-268.
10Rodbard HW, Blonde L, Braithwaite SS,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract, 2007,13 (Suppll) :1-68.
2Brunner-Schwarz A, Lill N. Acidic insulin preparations having improved stability. US 7,476,625 B2[P]. 2009.
3Dorschug M. A21-B30-modified insulin derivatives having an altered action profile. US, 5,656,722[P]. 1997.
4Dorschug. A21, B30, modified in derivatives having an altered action profile. US, 6,100,376[P]. 2000.
5http://www.drugbank.ca/drugs/DB 00047.
6Reynolds R L. Comparing insulin detemir and glargine in type 2 diabetes: more similarities than difference[J]. Postgrad Med, 2010, 122(2): 201-203.
7Hemkens L G . Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study[J]. Diabetologia, 2009, 52(9): 1732-1744.
